Go Pro
NASDAQ:HIND

Vyome Q2 2026 Earnings Report

$2.18 +0.02 (+0.93%)
Closing price 04:00 PM Eastern
Extended Trading
$2.17 -0.01 (-0.32%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vyome EPS Results

Actual EPS
-$0.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Vyome Revenue Results

Actual Revenue
$0.27 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vyome Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
Wednesday, August 12, 2026
Conference Call Time
7:00AM ET

Earnings Documents

Vyome Earnings Headlines

Vyome Holdings Inc HIND
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
See More Vyome Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vyome? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vyome and other key companies, straight to your email.

About Vyome

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

View Vyome Profile